Overview

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Status:
Not yet recruiting
Trial end date:
2029-10-09
Target enrollment:
Participant gender:
Summary
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca